BioSpace News Archive

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that the Company will report its second quarter 2023 financial results and provide a corporate update on Monday, August 14, 2023.

HDL Therapeutics, Inc., a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia, has signed a definitive merger agreement with Swiftmerge Acquisition Corp., a special purpose acquisition company with a disruptive consumer healthcare focused team.

Scientific Industries, Inc. announced it will file a Form 10Q after the close on August 14, 2023, for its second quarter financial results ended June 30, 2023, and issue a press release reporting its second quarter of 2023 after the market close on August 14, 2023.

With NETest, oncologists at leading cancer centers around the globe have a highly accurate molecular diagnostic to add to their patient care arsenal.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Illumina, Inc. announced that its vice president of investor relations will be speaking at the following investor conference.

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update.

CASI Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported financial results for the quarter ended June 30, 2023.

CareDx, Inc. (Nasdaq: CDNA) today commented on the issuance of proposed changes to the Local Coverage Determination (LCD) MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure®, AlloMap® and HeartCare.

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.